Advertisement

Effects of Long-Term Administration of Sandostatin® (SMS 201–995) at Increasing Doses in 40 Acromegalic Patients. Results from the French Sandostatin Acromegaly Study Group

  • G. Sassolas
  • P. Fossati
  • P. Chanson
  • R. Costa
  • B. Estour
  • A. Deidier
  • A. G. Harris
Conference paper

Abstract

Several studies demonstrate the efficacy of short- and long-term Sandostatin® treatment in acromegaly administered subcutaneously at doses ranging from 150 to 300 µg up to 600 µg per day [1, 3, 5, 7–10]. A rhythm of 3 injections per day has been shown to reduce the magnitude of the re-elevation of growth hormone (GH) which occurs before the following injection when Sandostatin is given only twice daily. However, some patients fail to respond adequately to the above-mentioned doses thus pointing to the possible need for higher doses of Sandostatin [1] or continuous subcutaneous infusion.

Keywords

Growth Hormone Pituitary Adenoma Acromegalic Patient Growth Hormone Concentration Tumor Size Reduction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Barnard LG, Grantham WG, Lamberton P, O’Dorisio TM, Jackson IMD (1986) Treatment of resistant acromegaly with a long-acting Somatostatin analogue (SMS 201-995). Ann Intern Med 105: 856–861CrossRefPubMedGoogle Scholar
  2. 2.
    Chanson P, Timsit J, Benoit O, Augendre B, Boulonguet M, Guillausseau PJ, Warnet A, Lubetzki J (1968) Rapid improvement in sleep apnoea of acromegaly after short-term treatment with somatostatin analogue SMS 201-995. Lancet ii: 1270–1271Google Scholar
  3. 3.
    Ch’ng LJC, Sandler LM, Kraenzlin ME, Burin JM, Joplin CF, Bloom SR (1985) Long-term treatment of acromegaly with a long-acting analogue of somatostatin. Br Med J 290: 284–288CrossRefGoogle Scholar
  4. 4.
    Comi RJ, Gesundheit N, Murray L, Gorden P, Weintraub BD (1987) Response of thyrotropin-secreting pituitary adenomas to a long-acting somatostatin analogue. N Engl J Med 317: 12–17CrossRefPubMedGoogle Scholar
  5. 5.
    Comi RJ, Gorden P (1987) The response of serum growth hormone levels to the long-acting somatostatin analog SMS 201-995 in acromegaly. J Clin Endocrinol Metab 64: 37–42CrossRefPubMedGoogle Scholar
  6. 6.
    Daughaday W (1985) A new treatment for an old disease. N Engl J Med 313: 1604–1605CrossRefPubMedGoogle Scholar
  7. 7.
    Lamberts SWJ, Oosterom R, Neufeld M, Del Pozo E (1985) The somatostatin analog SMS 201-995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients. J Clin Endocrinol Metab 60: 1161–1170CrossRefPubMedGoogle Scholar
  8. 8.
    Lamberts SJ, Uitterlinden P, Del Pozo E (1987) SMS 201-995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegaly for over two years. J Clin Endocrinol Metab 65: 703–710CrossRefPubMedGoogle Scholar
  9. 9.
    Lamberts SWJ, Uitterlinden P. Verschoor L, van Dongen KJ, Del Pozo E (1985) Longterm treatment of acromegaly with the somatostatin analogue SMS 201-995. N Engl J Med 313:1576— 1580Google Scholar
  10. 10.
    Plewe G, Beyer J, Krause U, Neufeld M, Del Pozo E (1984) Long-acting and selective suppression of growth hormone secretion by somatostatin analogue SMS 201-995 in acromegaly. Lancet II: 782–784Google Scholar

Copyright information

© Springer-Verlag, Berlin Heidelberg 1988

Authors and Affiliations

  • G. Sassolas
    • 1
  • P. Fossati
  • P. Chanson
  • R. Costa
  • B. Estour
  • A. Deidier
    • 2
  • A. G. Harris
    • 3
  1. 1.Centre de Médecine NucléaireLyonFrance
  2. 2.Recherches CliniquesSandozRueil MalmaisonFrance
  3. 3.Clinical ResearchSandoz LtdBasleSwitzerland

Personalised recommendations